Akebia Replaces $55 Million BlackRock Loan With $60 Million Borrowing And Share-Purchase Rights

The kidney-drug company can request another $80 million, but lenders decide whether to provide it.

Share
Akebia Replaces $55 Million BlackRock Loan With $60 Million Borrowing And Share-Purchase Rights

Akebia Therapeutics, which develops and sells kidney-disease medicines, replaced its $55 million BlackRock-managed loan with $60 million from healthcare lender Symbiotic Capital, according to an SEC filing Monday. The financing was funded Thursday and includes warrants — rights to buy Akebia shares — for lender affiliates.

Extra Borrowing Requires Lender Approval

Akebia received approximately $58.6 million after estimated financing costs, fees and expenses. It paid off the old loan in full, including termination fees and other expenses.

The company can request up to $80 million more, taking the facility's potential size to $140 million. Each lender and the agent can approve or reject that additional borrowing at their discretion.

The refinancing replaces an agreement Akebia signed on January 29, 2024, with Kreos Capital funds managed by BlackRock. The old lender's claims on company assets were released; the new debt is secured against substantially all borrower assets.

Interest Costs And Potential Dilution

Annual interest starts at 11.5%. When prime plus 4.5% is higher, Akebia pays that variable rate, subject to a 15% ceiling.

Lender affiliates received warrants to purchase 3,441,352 shares at an exercise price of about $0.70 per share. Those rights run through November 12, 2033, and exercising them would add shares to the outstanding count.

Any further borrowing triggers additional warrants. The number of shares equals 4% of the new funding divided by an exercise price based on the stock's average volume-weighted price over the preceding 30 trading days.

Early repayment carries additional costs: a premium of 1% to 3% before November 12, 2030, and interest through August 12, 2029, for repayments on or before that date. A 3.25% exit fee applies when principal is repaid.

Vafseo Sales Enter The Loan Tests

Akebia's commercial products are Vafseo, an oral treatment for kidney-disease anemia in adults on dialysis, and Auryxia. In the U.S., Auryxia treats elevated phosphorus in dialysis patients and iron deficiency anemia in adults with kidney disease who are not on dialysis.

If the agreement's cash measure reaches $40 million or less at a fiscal month-end, Akebia must keep at least $15 million and satisfy minimum total-revenue and Vafseo-revenue tests. That cash measure excludes certain overdue bills; the revenue tests cover trailing twelve-month periods beginning with the quarter ending December 31, 2026.

Akebia still expects existing cash and anticipated product, royalty, supply and license revenue to finance its operating plan for at least two years. Erik Ostrowski, Akebia's chief financial and chief business officer, said in Monday's release, "Today we also reaffirm our cash runway guidance of at least two years."

Akebia has no scheduled principal payments before November 12, 2031, when all outstanding principal comes due.

Sources

More on Akebia Therapeutics

All Akebia Therapeutics (AKBA) coverage →